DR-ROLANDO-CEDILLOS

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries

Haileyesus Getahun1 , Alberto Matteelli1 , Ibrahim Abubakar2,3, Mohamed Abdel Aziz4 , Annabel Baddeley1 , Draurio Barreira5 , Saskia Den Boon6 , Susana Marta Borroto Gutierrez7 , Judith Bruchfeld8 , Erlina Burhan9 , Solange Cavalcante10, Rolando Cedillos11,

ABSTRACT Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3–4 month isoniazid plus rifampicin; or 3–4 month rifampicin alone.

DR ROLANDO CEDILLOS

Novel HLA class I associations with HIV-1 control in a unique genetically admixed population

Humberto Valenzuela-Ponce1, Selma Alva-Hernández1, Daniela Garrido-Rodríguez1, Maribel Soto-Nava1, Thalía García-Téllez1,14, Tania Escamilla-Gómez1, Claudia GarcíaMorales1, Verónica Sonia Quiroz-Morales1, Daniela Tapia-Trejo1, Silvia del Arenal-Sánchez1, Francisco-Javier Prado-Galbarro 1, Ramón Hernández-Juan1, Edna Rodríguez-Aguirre1, Akio Murakami-Ogasawara1, Carlos Mejía-Villatoro2, Ingrid Y. Escobar-Urias2, Rodolfo Pinzón-Meza2, Juan Miguel Pascale3, Yamitzel Zaldivar3, Guillermo Porras-Cortés4, Carlos Quant-Durán5, Ivette Lorenzana6, Rita I. Meza7, Elsa Y. Palou8, Marvin Manzanero9, Rolando A. Cedillos10, Carmen Aláez 11, Mark A. Brockman 12,13, P. Richard Harrigan13, Chanson J. Brumme13, Zabrina L. Brumme12,13, Santiago Ávila-Ríos1, Gustavo Reyes-Terán1  

The Mesoamerican HIV Project Group* Associations between HLA class I alleles and HIV progression in populations exhibiting Amerindian and Caucasian genetic admixture remain understudied. Using univariable and multivariable analyses we evaluated HLA associations with fve HIV clinical parameters in 3,213 HIV clade B-infected, ARTnaïve individuals from Mexico and Central America (MEX/CAM cohort). A Canadian cohort (HOMER, n=1622) was used for comparison. As expected, HLA allele frequencies in MEX/CAM and HOMER difered markedly. In MEX/CAM, 13 HLA-A, 24 HLA-B, and 14 HLA-C alleles were signifcantly associated with at least one clinical parameter. These included previously described protective (e.g. B*27:05, B*57:01/02/03 and B*58:01) and risk (e.g. B*35:02) alleles, as well as novel ones (e.g. A*03:01, B*15:39 and B*39:02 identifed as protective, and A*68:03/05, B*15:30, B*35:12/14, B*39:01/06, B*39:05~C*07:02, and B*40:01~C*03:04 identifed as risk). Interestingly, both protective (e.g. B*39:02) and risk (e.g. B*39:01/05/06) subtypes were identifed within the common and genetically diverse HLAB*39 allele group, characteristic to Amerindian populations. While HLA-HIV associations identifed in MEX and CAM separately were similar overall (Spearman’s rho=0.33, p=0.03), region-specifc associations were also noted. The identifcation of both canonical and novel HLA/HIV associations provides a frst step towards improved understanding of HIV immune control among unique and understudied Mestizo populations.

Confirmed clinical case of chronic kidney disease of nontraditional causes in agricultural communities in Central America: a case definition for surveillance

Alejandro Ferreiro, Guillermo Álvarez-Estévez, Manuel Cerdas-Calderón, Zulma Cruz-Trujillo, Elio Mena,5 Marina Reyes, Mabel Sandoval-Diaz, Vicente Sánchez-Polo, Régulo Valdés, and Pedro Ordúnez

Over the last 20 years, many reports have described an excess of cases of chronic kidney disease (CKD) in the Pacific coastal area of Central America, mainly affecting male farmworkers and signaling a serious public health problem. Most of these cases are not associated with traditional risk factors for CKD, such as aging, diabetes mellitus, and hypertension. This CKD of nontraditional causes (CKDnT) might be linked to environmental and/or occupational exposure or working conditions, limited access to health services, and poverty. In response to a resolution approved by the Directing Council of the Pan American Health Organization (PAHO) in 2013, PAHO, the U.S. Centers for Disease Control and Prevention, and the Latin American Society of Nephrology and Hypertension (SLANH) organized a consultation process in order to expand knowledge on the epidemic of CKDnT and to develop appropriate surveillance instruments. The Clinical Working Group from SLANH was put in charge of finding a consensus definition of a confirmed clinical case of CKDnT. The resulting definition establishes mandatory criteria and exclusion criteria necessary for classifying a case of CKDnT. The definition includes a combination of universally accepted definitions of CKD and the main clinical manifestations of CKDnT. Based on the best available evidence, the Clinical Working Group also formulated general recommendations about clinical management that apply to any patient with CKDnT. Adhering to the definition of a confirmed clinical case of CKDnT and implementing it appropriately is expected to be a powerful instrument for understanding the prevalence of the epidemic, evaluating the results of interventions, and promoting appropriate advocacy and planning efforts294260391813810891674966693504718892695552n

 

Heat stress, dehydration, and kidney function in sugar cane cutters in El Salvador: A cross-shift study of workers at risk of Mesoamerican nephropathy.
Environmental Research 142 (2015) 746–755

Ramón García-Trabanino, Emmanuel Jarquín, Juan José Vindell 

Lic. Juan José Vindell G.

Lic. en Estadística Egresado de Maestria en Epidemiología CIES-UNAN

Esta dirección de correo electrónico está protegida contra spambots. Necesita activar JavaScript para visualizarla.

An epidemic of progressive kidney failure afflicts sugar cane workers in Central America.  Repeated high-intensity work in hot environments is a possible cause.
Objectives: To assess heat stress, dehydration, biomarkers of renal function and their possible associations. A secondary aim was to evaluate the prevalence of pre-shift renal damage and possible causal factors.


Methods: Sugar cane cutters (N 189, aged 18–49 years,168 of them male) from three regions in El Salvador were examined before and after shift. Cross-shift changes in markers of dehydration and renal function were examined and associations with temperature, worktime, region, and fluid intakewere assessed. Pre-shiftglomerular filtration rate was estimated (eGFR) from serum creatinine.

Results: The mean work-time was4(1.4–11) hours. Mean work day temperature was 34–36 °C before noon, and 39–42 °C at noon. The mean liquid intake during work was 0.8L per hour. There were statistically significant changes across shift. The mean urine specific gravity, urine osmolality and creatinine increased, and urinary pH decreased. Serum creatinine, uric acid and urea nitrogen increased, while chloride and potassium decreased. Pre-shift serum uric acid levels were remarkably high  and pre-shift eGFR  was reduced (less 60 mL/min) in 23 male workers (14%).
Conclusions: The high prevalence of reduced eGFR, and the cross-shift changes are consistent with recurrent dehydrati

on from strenuous work in a hot and humid environment as an important causal factor.
The pathophysiology may include decreased renal blood flow, high demands on tubular reabsorption,and increased levels of uric acid.

VINDELL

 
 
nefrol latinoam. 2 0 1 7;14(3):83–84
 
Raul G. Carlinia,∗ , María Nieves Campistrúsb , Liliana Andradec , Carlos Blancod , Liliana Chifflete , Zulma Carolina Cruz de Trujillof , María Eugênia Fernandes Canzianig , Thais A. Forsterh , Marcus Gomes Bastosi , Gregorio T. Obradorj , Jorge F.D. Pérez-Olivak , Hugo Poblete Badall y Fernando Renjel Claros
a Co-coordinador, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela
b Co-coordinadora, Comité de Educación Médica Continua, Sociedad Uruguaya de Nefrología, Montevideo, Uruguay
c Hospital Churruca Visca (PFA), Buenos Aires, Argentina
d Servicio de Nefrología, Hospital Aeronáutico Central, Buenos Aires, Argentina
e Fondo Nacional de Recursos, Montevideo, Uruguay
f Facultad de Medicina, Universidad de El Salvador, San Salvador, El Salvador
g Disciplina de Nefrología, Universidade Federal de São Paulo, São Paulo, Brasil
h Ciencias de Información en Salud, Montevideo, Uruguay
i Servic¸o de Nefrologia, Hospital Universitário da Universidade Federal de Juiz de Fora, Juiz de Fora, Brasil
j Escuela de Medicina, Universidad Panamericana, Ciudad de México, México
k Instituto Nacional de Nefrología «Dr. Abelardo Buch López», Universidad de Ciencias Médicas, La Habana, Cuba
l Centros de Diálisis Sermedial, Valparaíso y Vina˜ del Mar, Chile
m Facultad de Medicina, Universidad Mayor de San Simón, Cochabamba, Bolivia
 
 
El Comité de Anemia de la SLANH fue creado en 2007 con el objetivo primario de promover el adecuado tratamiento de la anemia en el paciente con ERC en LA, pretendiendo así reducir la morbimortalidad y mejorar la calidad de vida de estos enfermos. Para ello se consideró necesario unificar los criterios diagnósticos y de tratamiento a través de la elaboración y difusión de una guía latinoamericana para el tratamiento de la anemia en pacientes con ERC. Así es como se publicaron en 2009 las «Recomendaciones de práctica clínica de la Sociedad Latinoamericana de Nefrológia e Hipertensión (SLANH) para el tratamiento de la anemia en el paciente con ERC. Ese documento surgió de la revisión, por un grupo de expertos de diversos países de nuestro continente, de los trabajos científicos publicados hasta ese momento, así como de las GPC regionales e internacionales vigentes. Se procuró que el compendio de esa información resultara de fácil lectura, con sugerencias prácticas sobre el diagnóstico y el tratamiento de la anemia del paciente con ERC que pudieran ser aplicables en los países de LA.
La nueva actualización de 2017 fue creada, de manera similar a la publicación anterior, por un grupo de expertos nefrólogos en anemia de diversos países del nuestro continente. Esta nueva publicación presenta a los nefrólogos y médicos de LA que asisten pacientes con ERC un documento de apoyo igualmente práctico pero suficientemente actualizado que ofrece recomendaciones sobre el diagnóstico y los tratamientos más efectivos para los pacientes adultos portadores de ERC con anemia en cualquier etapa evolutiva de la enfermedad. No son considerados aspectos específicos relacionados al manejo de la anemia en ninos, ˜ en pacientes embarazadas ni en portadores de un trasplante renal funcionante, así como no pretende asumir situaciones clínicas complejas o no habituales.
 

http://www.elsevier.es/es-revista-nefrologia-latinoamericana-265-sumario-vol-14-num-3-S2444903217X00048

Busqueda

Siguenos en: